Mast Therapeutics Inc. and Savara Inc. said their proposed merged entity received approval to list on the Nasdaq Capital Market under ticker SVRA.
The companies first announced the proposed merger in January.
Though the merger has already been unanimously approved by the boards of both companies, it also needs to be approved by Mast shareholders at an upcoming April 21 special meeting.
Trading of the new company on the Nasdaq is expected to start on the first business day after completion of the merger. Until then Mast will continue to trade on the NYSE MKT.